In Poland, the diagnosis of EGFR gene mutations is performed in patients with non-squamous cell carcinoma and, until recently, only in patients with advanced NSCLC (due to the reimbursement regulations for EGFR tyrosine kinase inhibitors therapy). Here, EGFR is linked to squamous cell carcinoma.